London, November 11, 2021 – Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures, has participated in a seed financing round for BioSapien Inc., a venture-backed biotechnology company focused on innovative therapies to transform patient care.
BioSapien is a developer of 3D-printed biodegradable implantable devices intended to deliver FDA-approved drugs directly to cancerous cells.
The company’s device, MediChip®, is a novel 3D-printed biodegradable mesh that is intended to allow for chemotherapy to be delivered intravenously through a controlled drug release, with the aim of enabling physicians to reduce harmful side-effects and costs.
“As so many have witnessed or experienced first-hand, the effects of chemotherapy can take a tremendous toll on the immune system and body of patients undergoing treatment for cancer.
We are excited to be an early investor in BioSapien and their novel drug delivery system, which has the potential to revolutionize the delivery of chemotherapy through a targeted, personalized, and controlled approach to alleviate the unwanted side effects and toxicities of the treatment.” said Hamzeh Abdul-Hadi, Principal at Hikma Ventures.
“We are also strong supporters of BioSapien’s leadership team, led by CEO and Co-Founder Dr. Khatija Ali, and are proud to continue supporting female founders, who now comprise more than 20% of our investment portfolio.”
“Hikma Ventures is a strong addition to our investor syndicate and we are extremely pleased to have such an experienced partner supporting our work to transform patient care,” said Dr. Khatija Ali, CEO and Co-Founder of BioSapien. “The seed round funds will advance development of MediChip® and give access to global distribution channels and manufacturing.”
